How India Exports Iron to the World

Iron-containing pharmaceutical products are subject to stringent regulatory oversight by the U.S. Food and Drug Administration (FDA). Manufacturers seeking to market generic iron supplements in the United States must submit an Abbreviated New Drug Application (ANDA) to demonstrate bioequivalence to a reference listed drug (RLD). According to the FDA's Orange Book, numerous ANDAs for iron formulations have been approved, indicating a competitive market landscape.

The FDA employs Import Alerts to prevent the entry of products that appear to violate U.S. regulations. For instance, Import Alert 66-66, issued in October 2024, targets active pharmaceutical ingredients (APIs) that are misbranded due to inadequate labeling. While this alert is not specific to iron products, it underscores the importance of compliance with FDA labeling requirements for all pharmaceutical imports.

Given that 74.8% of India's iron exports are destined for the United States, it is imperative for Indian exporters to adhere strictly to FDA regulations to maintain market access.

In the European Union (EU) and the United Kingdom (UK), iron-containing medicinal products require marketing authorization from the European Medicines Agency (EMA) or the UK's Medicines and Healthcare products Regulatory Agency (MHRA), respectively. Applicants must provide comprehensive data on product quality, safety, and efficacy. Manufacturing sites, including those outside the EU, must comply with EU Good Manufacturing Practice (GMP) standards. The EMA mandates that all manufacturing sites involved in the production and testing of medicinal products be identified in the marketing authorization application, with detailed descriptions of their roles. (ema.europa.eu)

Compliance with these regulatory requirements is essential for Indian exporters targeting the EU and UK markets.

Iron supplements are included in the World Health Organization's (WHO) Model List of Essential Medicines, highlighting their importance in addressing global health needs. The WHO Prequalification Programme sets international standards for the quality, safety, and efficacy of medicinal products, including iron formulations. Additionally, iron products must comply with pharmacopoeial standards such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, iron-containing pharmaceuticals are classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including certain iron formulations, to ensure affordability. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

The patent landscape for iron supplements is relatively mature, with many patents having expired, allowing for robust generic competition. This competitive environment is reflected in the significant number of ANDAs approved by the FDA for iron products.

In April 2024, the Federal Trade Commission (FTC) expanded its scrutiny of pharmaceutical patent listings, challenging over 300 "junk" patents related to various drugs, including those for diabetes and weight loss. While not directly targeting iron products, this action underscores the regulatory focus on ensuring fair competition in the pharmaceutical market.

In August 2025, the FDA issued Import Alert 66-57, targeting foreign-manufactured unapproved prescription drugs distributed to individuals in the U.S. This alert emphasizes the FDA's commitment to preventing the entry of unapproved drugs into the U.S. market.

These developments highlight the dynamic regulatory environment affecting pharmaceutical exports, including iron products, and the need for exporters to stay informed and compliant with evolving regulations.

India's pharmaceutical industry, including iron-based formulations, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of these essential components are sourced from China, creating a significant dependency. This reliance exposes the supply chain to vulnerabilities, as any disruption in Chinese production or export policies can directly impact the availability and cost of APIs in India.

Recent events have highlighted these risks. In February 2025, the FDA issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practices (cGMP). Such regulatory actions can lead to production halts or restrictions, further straining the supply chain.

Our proprietary trade data indicates a high supplier concentration in India's iron exports. The top five exporters account for 65.6% of the total export value, with ZYDUS LIFESCIENCES LIMITED alone contributing 27.4%. This concentration poses a single-source risk; any operational or compliance issues within these key companies could disrupt a significant portion of the supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic manufacturing of APIs and reducing import dependence. As of November 2024, two greenfield plants were inaugurated under this scheme to produce critical molecules like Penicillin G and Clavulanic Acid, which had not been manufactured domestically for over two decades. These initiatives are steps toward diversifying the supplier base and enhancing supply chain resilience.

Global geopolitical tensions and shipping disruptions further exacerbate supply chain risks. Incidents in strategic maritime routes such as the Red Sea and the Strait of Hormuz can delay shipments and increase transportation costs. Additionally, escalating tensions between the U.S. and China have led to trade restrictions and tariffs, impacting the global pharmaceutical supply chain. The FDA has issued shortage alerts for various medications, underscoring the fragility of the current supply network.

To enhance the resilience of India's iron export supply chain, the following actions are recommended:

• Diversify API and KSM Sources: Encourage the development of alternative domestic and international suppliers to reduce dependency on a single country.

• Strengthen Domestic Manufacturing: Expand the PLI scheme to cover a broader range of APIs and KSMs, providing incentives for local production.

• Enhance Regulatory Compliance: Implement stringent quality control measures to ensure compliance with international standards, reducing the risk of regulatory actions that can disrupt production.

• Develop Strategic Reserves: Establish reserves of critical APIs and KSMs to buffer against short-term supply disruptions.

• Invest in Infrastructure: Improve port facilities and logistics networks to mitigate the impact of shipping disruptions and ensure timely delivery of exports.

RISK_LEVEL: HIGH